| Literature DB >> 31353319 |
Dagmar E Ehrnhoefer1, Niels H Skotte2, Jeanette Reinshagen3, Xiaofan Qiu2, Björn Windshügel3, Priyadarshini Jaishankar4, Safia Ladha2, Olga Petina5, Mehdi Khankischpur5, Yen T N Nguyen2, Nicholas S Caron2, Adelia Razeto3, Matthias Meyer Zu Rheda3, Yu Deng2, Khuong T Huynh2, Ilka Wittig6, Philip Gribbon3, Adam R Renslo4, Detlef Geffken5, Sheraz Gul3, Michael R Hayden2.
Abstract
Aberrant activation of caspase-6 (C6) in the absence of other hallmarks of apoptosis has been demonstrated in cells and tissues from patients with Huntington disease (HD) and animal models. C6 activity correlates with disease progression in patients with HD and the cleavage of mutant huntingtin (mHTT) protein is thought to strongly contribute to disease pathogenesis. Here we show that the mHTT1-586 fragment generated by C6 cleavage interacts with the zymogen form of the enzyme, stabilizing a conformation that contains an active site and is prone to full activation. This shift toward enhanced activity can be prevented by a small-molecule inhibitor that blocks the interaction between C6 and mHTT1-586. Molecular docking studies suggest that the inhibitor binds an allosteric site in the C6 zymogen. The interaction of mHTT1-586 with C6 may therefore promote a self-reinforcing, feedforward cycle of C6 zymogen activation and mHTT cleavage driving HD pathogenesis.Entities:
Keywords: Huntington disease; allosteric; caspase-6; inhibitor; non-apoptotic
Year: 2019 PMID: 31353319 PMCID: PMC6754302 DOI: 10.1016/j.chembiol.2019.07.001
Source DB: PubMed Journal: Cell Chem Biol ISSN: 2451-9448 Impact factor: 8.116